Spinal Cord Injury Stem Cell Therapy Development

Stem cell therapy for spinal cord injury (SCI) is an innovative and promising approach in the field of regenerative medicine. It involves the use of stem cells to potentially repair damaged spinal cord tissue and promote functional recovery in individuals who have experienced SCI. CD BioSciences offers stem cell therapy development services for SCI, based on out advanced technology and professional team.

Introduction into Spinal Cord Injury

A spinal cord injury (SCI) is a traumatic medical condition that results from damage to the spinal cord, a vital part of the central nervous system. The spinal cord is a bundle of nerves that runs from the base of the brain down the back, protected by the vertebrae of the spine. It plays a crucial role in transmitting signals between the brain and the rest of the body, allowing for the control of movement, sensation, and various bodily functions.

Fig 1. Types of SCI

Spinal cord injuries often result from traumatic events, such as car accidents, falls, sports injuries, or acts of violence. They can also occur due to non-traumatic causes like infections, tumors, or degenerative diseases.

Stem Cell Therapy for Spinal Cord Injury

Clinical Trials and Stem Cells Used in SCI

Cell Type	Administration Route	Time from Injury (acute/subacute/chronic phase)	Main Outcome (Functional Improvement/Adverse Effects)
BMSC	Intravenous	Subacute	AIS A→B (3/6 patients), A→C (2/6), B→C (1/2), B→D (1/2), C→D (5/5). Functional improvements according to ISCSCI-92 and SCIM-III scales.
	Intrathecal x1 Intravenous x6	Chronic	AIS A→C. Increase in AIS score: 10→30. Increase in MRC score for L1 and L2 innervated muscles: 0/5→3/5.
	Intrathecal	Chronic	AIS improvement in 27% of patients.
	Intramedullary	Chronic	AIS improvement in 2 patients. Bowel and bladder function improved. 4 patients improved in NCS findings.
	Intrathecal	Chronic	Improvement in functionality and especially in Krogh's Neurogenic Bowel Dysfunction scale.
	Intrathecal	Chronic	AIS Improvement. Motor and sensory scores improved.
UCMSC	Intramedullary	Acute	AIS A→B (9 patients), AIS A→C (2patients). Improvement in ADL scores. Improvement in bowel and bladder function.
	Intrathecal	Subacute or Chronic	Statistical increase in AIS and IANR-SCIRFS scores. Decrease in muscle spasticity. No serious adverse effects.
	Intramedullary	Acute	AIS A→C in both patients.
WJ-MSC	Intrathecal	Chronic	Significant improvement in pinprick sensation in compared with placebo group. No changes in motor function, independence, QoL, SEPs, MEPs, spasticity or bowel function.
huCNS-SC	Intramedullary	Subacute or Chronic	Sensory improvements in 5 out of 12 patients. No motor improvements were observed.
	Intramedullary	Subacute or Chronic	Trial terminated prematurely by sponsor. Improvement in UEMS score. No adverse effects.
	Intramedullary	Subacute	Improvement in AIS motor scores. 15 serious adverse effects in cervical group and 4 in thoracic.

Our Services

CD BioSciences offers stem cell therapy development service for spinal cord injury based on our advanced technology and professional team. Our stem cell therapy development services are accessible in stem cells included but not limited as follows:

Mesenchymal Stem Cells
Bone Marrow-derived Mesenchymal Stem Cells
Umbilical Cord Mesenchymal Stem Cells
Umbilical Cord Wharton-Jelly Mesenchymal Stem Cells

Neural Stem Cells
Human Central Nervous System Stem Cells
Human Umbilical Cord Blood Cells

As a pioneer in biotechnology, CD BioSciences has grown into one of the largest independent biotechnology companies in the world. CD BioSciences is committed to providing professional and efficient service to our customers around the world. If you are interested in our service, please contact us.

Reference

Shaimardanova, Alisa A et al. "Metachromatic Leukodystrophy: Diagnosis, Modeling, and Treatment Approaches." Frontiers in medicine vol. 7 576221. 20 Oct. 2020.

For research use only, not for clinical use.